At Princess Alexandra Hospital in Brisbane, researchers have discovered something quietly revolutionary: a single blood test that could tell doctors whether lung cancer patients will respond to treatment before therapy even begins. Associate Professor Arutha Kulasinghe and his team at the University of Queensland's Frazer Institute have spent years analyzing what's already hiding in patients' bloodstreams — thousands of proteins that hold the key to personalized cancer care.
Non-small cell lung cancer is the most common form of the disease, and it kills more people than any other type of cancer globally. Treatment decisions have long been made in the dark: clinicians choose between expensive immunotherapies and surgery without knowing who will benefit. Immunotherapy alone can cost patients up to half a million dollars a year, making those decisions feel impossibly high-stakes. Kulasinghe's research, published in npj Precision Oncology, changes that equation by making the invisible visible.
The study tracked blood samples from NSCLC patients before and after surgery and immunotherapy, measuring thousands of proteins and using advanced statistical modeling to identify which protein patterns predicted treatment response and disease progression. By analyzing how protein levels shifted over time in response to therapy, the researchers could distinguish between patients who would improve and those who wouldn't. The findings were validated using an independent testing platform, adding confidence to the discovery.
"What we're showing is that information already exists in the blood," Kulasinghe said. The implications ripple outward immediately. Dr. Aaron Kilgallon from the Queensland Spatial Biology Center, a collaboration between the University of Queensland and Wesley Research Institute, notes that blood-based monitoring would spare patients the burden of repeat biopsies — a far less invasive way to track disease progression. More importantly, it could give doctors earlier warning of cancer recurrence, shifting from reactive to proactive care.
For patients, this represents a fundamental shift. Rather than enduring expensive treatments that might not work, tailored decisions based on protein signatures in the blood could mean faster paths to effective therapy or quicker pivots to alternative approaches. It's the difference between hoping a treatment works and knowing, before you start, that it likely will.
The team is already thinking bigger. While further research is needed before this blood test enters clinical practice, researchers are exploring whether the method can be applied to other cancers beyond lung disease. Kulasinghe's vision is clear: use each patient's own biology as a guide, right at the moment of diagnosis, to shape the entire treatment journey ahead. For the millions facing lung cancer diagnoses each year, personalized medicine is no longer a distant dream — it's emerging from a small vial of blood.